Next Article in Journal / Special Issue
Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results
Previous Article in Journal / Special Issue
A New Cold Plasma Jet: Performance Evaluation of Cold Plasma, Hybrid Plasma and Argon Plasma Coagulation
Article Menu

Export Article

Open AccessArticle
plasma 2018, 1(1), 201-217; https://doi.org/10.3390/plasma1010018 (registering DOI)

Plasma Treatment of Ovarian Cancer Cells Mitigates Their Immuno-Modulatory Products Active on THP-1 Monocytes

1
ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, 17489 Greifswald, Germany
2
Department of Gynaecology and Obstetrics, University Medical Center Greifswald, 17475 Greifswald, Germany
3
Department of Urology, University Medical Center Greifswald, 17475 Greifswald, Germany
*
Author to whom correspondence should be addressed.
Received: 1 August 2018 / Revised: 8 September 2018 / Accepted: 14 September 2018 / Published: 15 September 2018
(This article belongs to the Special Issue Plasma Medicine)
Full-Text   |   PDF [2262 KB, uploaded 15 September 2018]   |  

Abstract

Cancers modulate their microenvironment to favor their growth. In particular, monocytes and macrophages are targeted by immuno-modulatory molecules installed by adjacent tumor cells such as ovarian carcinomas. Cold physical plasma has recently gained attention as innovative tumor therapy. We confirmed this for the OVCAR-3 and SKOV-3 ovarian cancer cell lines in a caspase 3/7 independent and dependent manner, respectively. To elaborate whether plasma exposure interferes with their immunomodulatory properties, supernatants of control and plasma-treated tumor cells were added to human THP-1 monocyte cultures. In the latter, modest effects on intracellular oxidation or short-term metabolic activity were observed. By contrast, supernatants of plasma-treated cancer cells abrogated significant changes in morphological and phenotypic features of THP-1 cells compared to those cultured with supernatants of non-treated tumor cell counterparts. This included cell motility and morphology, and modulated expression patterns of nine cell surface markers known to be involved in monocyte activation. This was particularly pronounced in SKOV-3 cells. Further analysis of tumor cell supernatants indicated roles of small particles and interleukin 8 and 18, with MCP1 presumably driving activation in monocytes. Altogether, our results suggest plasma treatment to alleviate immunomodulatory secretory products of ovarian cancer cells is important for driving a distinct myeloid cell phenotype. View Full-Text
Keywords: kINPen; plasma medicine; tumor immunology; ovarian cancer kINPen; plasma medicine; tumor immunology; ovarian cancer
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bekeschus, S.; Wulf, C.P.; Freund, E.; Koensgen, D.; Mustea, A.; Weltmann, K.-D.; Stope, M.B. Plasma Treatment of Ovarian Cancer Cells Mitigates Their Immuno-Modulatory Products Active on THP-1 Monocytes. plasma 2018, 1, 201-217.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
plasma EISSN 2571-6182 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top